Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-30 @ 9:32 AM
Study NCT ID:
NCT01137994
Status:
WITHDRAWN
Last Update Posted:
2013-03-13
First Post:
2010-06-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
113333
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None